132 related articles for article (PubMed ID: 29308069)
1. Orally administered endoxifen inhibits tumor growth in melanoma-bearing mice.
Chen P; Sheikh S; Ahmad A; Ali SM; Ahmad MU; Ahmad I
Cell Mol Biol Lett; 2018; 23():3. PubMed ID: 29308069
[TBL] [Abstract][Full Text] [Related]
2. The combination of the antiestrogen endoxifen with all-trans-retinoic acid has anti-proliferative and anti-migration effects on melanoma cells without inducing significant toxicity in non-neoplasic cells.
Ribeiro MP; Silva FS; Paixão J; Santos AE; Custódio JB
Eur J Pharmacol; 2013 Sep; 715(1-3):354-62. PubMed ID: 23712006
[TBL] [Abstract][Full Text] [Related]
3. Orally administered endoxifen is a new therapeutic agent for breast cancer.
Ahmad A; Ali SM; Ahmad MU; Sheikh S; Ahmad I
Breast Cancer Res Treat; 2010 Jul; 122(2):579-84. PubMed ID: 20052538
[TBL] [Abstract][Full Text] [Related]
4. Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenografts.
Gong IY; Teft WA; Ly J; Chen YH; Alicke B; Kim RB; Choo EF
Breast Cancer Res Treat; 2013 May; 139(1):61-9. PubMed ID: 23605084
[TBL] [Abstract][Full Text] [Related]
5. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.
Lim YC; Desta Z; Flockhart DA; Skaar TC
Cancer Chemother Pharmacol; 2005 May; 55(5):471-8. PubMed ID: 15685451
[TBL] [Abstract][Full Text] [Related]
6. The effects of a novel hormonal breast cancer therapy, endoxifen, on the mouse skeleton.
Gingery A; Subramaniam M; Pitel KS; Reese JM; Cicek M; Lindenmaier LB; Ingle JN; Goetz MP; Turner RT; Iwaniec UT; Spelsberg TC; Hawse JR
PLoS One; 2014; 9(5):e98219. PubMed ID: 24853369
[TBL] [Abstract][Full Text] [Related]
7. BF-30 selectively inhibits melanoma cell proliferation via cytoplasmic membrane permeabilization and DNA-binding in vitro and in B16F10-bearing mice.
Wang H; Ke M; Tian Y; Wang J; Li B; Wang Y; Dou J; Zhou C
Eur J Pharmacol; 2013 May; 707(1-3):1-10. PubMed ID: 23541725
[TBL] [Abstract][Full Text] [Related]
8. The systemic administration of lethal toxin achieves a growth delay of human melanoma and neuroblastoma xenografts: assessment of receptor contribution.
Rouleau C; Menon K; Boutin P; Guyre C; Yoshida H; Kataoka S; Perricone M; Shankara S; Frankel AE; Duesbery NS; Vande Woude G; Biemann HP; Teicher BA
Int J Oncol; 2008 Apr; 32(4):739-48. PubMed ID: 18360701
[TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration.
Iusuf D; Teunissen SF; Wagenaar E; Rosing H; Beijnen JH; Schinkel AH
J Pharmacol Exp Ther; 2011 Jun; 337(3):710-7. PubMed ID: 21378205
[TBL] [Abstract][Full Text] [Related]
10. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells.
Wu X; Hawse JR; Subramaniam M; Goetz MP; Ingle JN; Spelsberg TC
Cancer Res; 2009 Mar; 69(5):1722-7. PubMed ID: 19244106
[TBL] [Abstract][Full Text] [Related]
11. Phenothiazines induce apoptosis in a B16 mouse melanoma cell line and attenuate in vivo melanoma tumor growth.
Gil-Ad I; Shtaif B; Levkovitz Y; Nordenberg J; Taler M; Korov I; Weizman A
Oncol Rep; 2006 Jan; 15(1):107-12. PubMed ID: 16328041
[TBL] [Abstract][Full Text] [Related]
12. Thiabendazole, a well-known antifungal drug, exhibits anti-metastatic melanoma B16F10 activity via inhibiting VEGF expression and inducing apoptosis.
Zhang J; Zhao C; Gao Y; Jiang Y; Liang H; Zhao G
Pharmazie; 2013 Dec; 68(12):962-8. PubMed ID: 24400443
[TBL] [Abstract][Full Text] [Related]
13. Profound reduction in tamoxifen active metabolite endoxifen in a breast cancer patient treated with rifampin prior to initiation of an anti-TNFα biologic for ulcerative colitis: a case report.
Henderson SL; Teft WA; Kim RB
BMC Cancer; 2016 May; 16():304. PubMed ID: 27169677
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo effect of IFNalpha on B16F10 melanoma in two models: subcutaneous (C57BL6J mice) and lung metastasis (Swiss mice).
Martínez Conesa C; Alvarez Sánchez N; Vicente Ortega V; García Reverte J; Pascual Carpe F; Campos Aranda M
Biomed Pharmacother; 2009 May; 63(4):305-12. PubMed ID: 19171452
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.
Hertz DL; Deal A; Ibrahim JG; Walko CM; Weck KE; Anderson S; Magrinat G; Olajide O; Moore S; Raab R; Carrizosa DR; Corso S; Schwartz G; Graham M; Peppercorn JM; Jones DR; Desta Z; Flockhart DA; Evans JP; McLeod HL; Carey LA; Irvin WJ
Oncologist; 2016 Jul; 21(7):795-803. PubMed ID: 27226358
[TBL] [Abstract][Full Text] [Related]
16. Comparative uterotrophic effects of endoxifen and tamoxifen in ovariectomized Sprague-Dawley rats.
Schweikart KM; Eldridge SR; Safgren SL; Parman T; Reid JM; Ames MM; Goetz MP; Davis MA
Toxicol Pathol; 2014 Dec; 42(8):1188-96. PubMed ID: 24670817
[TBL] [Abstract][Full Text] [Related]
17. A prospective case series of women with estrogen receptor-positive breast cancer: levels of tamoxifen metabolites in controlled ovarian stimulation with high-dose tamoxifen.
Balkenende EM; Dahhan T; Linn SC; Jager NG; Beijnen JH; Goddijn M
Hum Reprod; 2013 Apr; 28(4):953-9. PubMed ID: 23335608
[TBL] [Abstract][Full Text] [Related]
18. Oral treatment with a rattlesnake native polypeptide crotamine efficiently inhibits the tumor growth with no potential toxicity for the host animal and with suggestive positive effects on animal metabolic profile.
Campeiro JD; Marinovic MP; Carapeto FC; Dal Mas C; Monte GG; Carvalho Porta L; Nering MB; Oliveira EB; Hayashi MAF
Amino Acids; 2018 Feb; 50(2):267-278. PubMed ID: 29235017
[TBL] [Abstract][Full Text] [Related]
19. The anticancer drug metabolites endoxifen and 4-hydroxy-tamoxifen induce toxic effects on Daphnia pulex in a two-generation study.
Borgatta M; Decosterd LA; Waridel P; Buclin T; Chèvre N
Sci Total Environ; 2015 Jul; 520():232-40. PubMed ID: 25817760
[TBL] [Abstract][Full Text] [Related]
20. Effect of Wf-536, a novel ROCK inhibitor, against metastasis of B16 melanoma.
Nakajima M; Hayashi K; Egi Y; Katayama K; Amano Y; Uehata M; Ohtsuki M; Fujii A; Oshita K; Kataoka H; Chiba K; Goto N; Kondo T
Cancer Chemother Pharmacol; 2003 Oct; 52(4):319-24. PubMed ID: 12783205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
